CEREVEL THERAPEUTICS HLDNG I's ticker is CERE and the CUSIP is 15678U128. A total of 109 filers reported holding CEREVEL THERAPEUTICS HLDNG I in Q4 2021. The put-call ratio across all filers is 0.33 and the average weighting 0.3%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $30,496 | -77.5% | 1,397 | -67.2% | 0.00% | -80.0% |
| Q2 2023 | $135,489 | +208344.6% | 4,262 | +59.4% | 0.01% | +150.0% |
| Q1 2023 | $65 | -44.9% | 2,674 | -28.6% | 0.00% | -60.0% |
| Q4 2022 | $118 | -99.9% | 3,747 | -19.4% | 0.01% | +150.0% |
| Q3 2022 | $131,000 | -18.6% | 4,649 | -23.6% | 0.00% | -50.0% |
| Q2 2022 | $161,000 | -16.1% | 6,084 | +10.5% | 0.00% | +100.0% |
| Q1 2022 | $192,000 | +1.6% | 5,506 | -5.6% | 0.00% | -33.3% |
| Q4 2021 | $189,000 | -47.1% | 5,830 | -51.8% | 0.00% | -66.7% |
| Q3 2021 | $357,000 | +792.5% | 12,093 | +678.2% | 0.01% | +800.0% |
| Q2 2021 | $40,000 | +400.0% | 1,554 | +155.2% | 0.00% | – |
| Q1 2021 | $8,000 | +300.0% | 609 | +509.0% | 0.00% | – |
| Q4 2020 | $2,000 | – | 100 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| BAIN CAPITAL INVESTORS LLC | 60,632,356 | $1,005,284,000 | 38.09% |
| Ally Bridge Group (NY) LLC | 1,767,440 | $29,304,000 | 5.02% |
| Affinity Asset Advisors, LLC | 270,000 | $4,477,000 | 2.37% |
| SPHERA FUNDS MANAGEMENT LTD. | 811,665 | $13,457,000 | 1.19% |
| Artal Group S.A. | 2,282,100 | $37,837,000 | 0.81% |
| Perceptive Advisors | 4,544,062 | $75,340,000 | 0.81% |
| RA Capital Management | 2,200,000 | $36,476,000 | 0.51% |
| Monashee Investment Management LLC | 200,000 | $3,316,000 | 0.44% |
| Boxer Capital, LLC | 714,500 | $11,846,000 | 0.38% |
| EcoR1 Capital, LLC | 400,000 | $6,632,000 | 0.36% |